BioLife Solutions, Inc.
BLFSHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeHeadquartered within the healthcare sector, BioLife Solutions, Inc. focuses on Medical Instruments & Supplies services and products. BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. At a $1.72B market cap, BioLife Solutions, Inc. ranks as a small-cap company within healthcare. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Market Cap
$1.72B
Beta
1.92
P/E (TTM)
35.25
P/E (Fwd)
106.82
EPS (TTM)
$1.00
EPS (Fwd)
$0.33
ROE
12.8%
ROA
0.3%
Cash
$82.4M
Total Debt
$15.7M
Free CF
$4.7M
52W Change
33.5%
Annual Financials
Cash vs Debt
Where BLFS stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, BLFS finished 46.64% above its 150-day moving average ($25.28) and 46.93% above its 200-day moving average ($25.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BLFS overbought or oversold?
At the September 1, 2026 close, BLFS's RSI(14) was 69.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $82.4M in cash and $15.7M in debt, BLFS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $4.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 12.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $76.2M (2022) to $96.2M (2025), reflecting a 26% increase over the period.
A beta of 1.92 means BLFS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, BLFS has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioLife Solutions, Inc. and its sector.